Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
21 Apr 2022
21 Apr 2022
Historique:
received:
15
07
2021
accepted:
14
03
2022
entrez:
22
4
2022
pubmed:
23
4
2022
medline:
23
4
2022
Statut:
epublish
Résumé
Many patients discontinue endocrine therapy for breast cancer due to intolerance. Identification of patients at risk for discontinuation is challenging. The minimal important difference (MID) is the smallest change in a score on a patient-reported outcome (PRO) that is clinically significant. We evaluated the association between treatment-emergent symptoms detected by worsening PRO scores in units equal to the MID with discontinuation. We enrolled females with stage 0-III breast cancer initiating endocrine therapy in a prospective cohort. Participants completed PROs at baseline, 3, 6, 12, 24, 36, 48, and 60 months. Measures included PROMIS pain interference, fatigue, depression, anxiety, physical function, and sleep disturbance; Endocrine Subscale of the FACT-ES; and MOS-Sexual Problems (MOS-SP). We evaluated associations between continuous PRO scores in units corresponding to MIDs (PROMIS: 4-points; FACT-ES: 5-points; MOS-SP: 8-points) with time to endocrine therapy discontinuation using Cox proportional hazards models. Among 321 participants, 140 (43.6%) initiated tamoxifen and 181 (56.4%) initiated aromatase inhibitor (AI). The cumulative probability of discontinuation was 23% (95% CI 18-27%) at 48 months. For every 5- and 4-point worsening in endocrine symptoms and sleep disturbance respectively, participants were 13 and 14% more likely to discontinue endocrine therapy respectively (endocrine symptoms HR 1.13, 95% CI 1.02-1.25, p = 0.02; sleep disturbance HR 1.14, 95% CI 1.01-1.29, p = 0.03). AI treatment was associated with greater likelihood of discontinuation than tamoxifen. Treatment-emergent endocrine symptoms and sleep disturbance are associated with endocrine therapy discontinuation. Monitoring for worsening scores meeting or exceeding the MID on PROs may identify patients at risk for discontinuation.
Identifiants
pubmed: 35449210
doi: 10.1038/s41523-022-00414-0
pii: 10.1038/s41523-022-00414-0
pmc: PMC9023490
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53Informations de copyright
© 2022. The Author(s).
Références
Breast Cancer Res Treat. 2018 Nov;172(1):167-177
pubmed: 30030708
Breast Cancer Res Treat. 2018 Jun;169(3):537-548
pubmed: 29455298
Oncologist. 2016 May;21(5):539-46
pubmed: 27009936
JCO Clin Cancer Inform. 2019 Apr;3:1-9
pubmed: 31002563
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
J Pain Symptom Manage. 2013 May;45(5):811-21
pubmed: 23017624
J Oncol Pract. 2017 May;13(5):e451-e462
pubmed: 28287854
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922787
BMC Cancer. 2013 Sep 03;13:401
pubmed: 24004677
Ann Oncol. 2018 Feb 1;29(2):504-509
pubmed: 29126161
J Clin Oncol. 2003 Feb 15;21(4):602-6
pubmed: 12586795
Lancet Oncol. 2017 Nov;18(11):1502-1511
pubmed: 29031778
Patient. 2018 Dec;11(6):591-598
pubmed: 29968179
Breast. 2015 Oct;24(5):630-6
pubmed: 26189978
JCO Oncol Pract. 2020 Sep;16(9):e958-e965
pubmed: 32463762
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD007566
pubmed: 22895961
Breast Cancer Res Treat. 2018 Feb;167(3):615-633
pubmed: 29110151
Breast Cancer Res Treat. 2010 Aug;122(3):843-51
pubmed: 20058066
J Clin Epidemiol. 2016 May;73:119-27
pubmed: 26931289
J Biopharm Stat. 2004 Feb;14(1):73-96
pubmed: 15027501
Breast Cancer Res Treat. 2014 Jun;145(2):525-34
pubmed: 24781972
Qual Life Res. 2009 Sep;18(7):793-800
pubmed: 19544089
Breast Cancer Res Treat. 2011 Apr;126(2):529-37
pubmed: 20803066
J Clin Oncol. 2020 Jul 1;38(19):2122-2129
pubmed: 32369401
Support Care Cancer. 2014 Apr;22(4):937-45
pubmed: 24271937
Springerplus. 2014 Jun 04;3:282
pubmed: 24936397
J Clin Oncol. 2017 Jun 10;35(17):1913-1920
pubmed: 28426375
Palliat Support Care. 2018 Jun;16(3):325-334
pubmed: 28508735
Cancer. 2017 Jan 1;123(2):327-335
pubmed: 27696377
Breast Cancer Res Treat. 2020 Jun;181(2):347-359
pubmed: 32274665
N Engl J Med. 2003 Nov 6;349(19):1793-802
pubmed: 14551341
J Clin Oncol. 2010 Sep 20;28(27):4120-8
pubmed: 20585090
Breast Cancer Res Treat. 2012 Jan;131(2):491-9
pubmed: 21976056
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Breast Cancer Res Treat. 2013 Feb;137(3):829-36
pubmed: 23263740
Breast Cancer Res Treat. 2016 May;157(1):133-43
pubmed: 27086286
Ann Oncol. 2014 Feb;25(2):372-7
pubmed: 24355487
Menopause. 2017 May;24(5):517-523
pubmed: 27875389
Lancet. 2016 Feb 27;387(10021):857-65
pubmed: 26686960
Breast Cancer Res Treat. 2015 Jul;152(2):239-46
pubmed: 26077640
Breast Cancer Res Treat. 2006 Sep;99(2):215-20
pubmed: 16541307
Integr Cancer Ther. 2013 Jul;12(4):323-35
pubmed: 22831916
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 27901302
Menopause. 2013 Jan;20(1):15-21
pubmed: 22948136
Am J Phys Med Rehabil. 2014 Aug;93(8):675-86
pubmed: 24743466
J Oncol Pract. 2012 Nov;8(6):e149-57
pubmed: 23598850
Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134
pubmed: 30231381
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Eur J Cancer. 2018 Jun;96:82-90
pubmed: 29679775
Breast. 2016 Jun;27:116-21
pubmed: 27065357
J Clin Epidemiol. 2011 May;64(5):507-16
pubmed: 21447427
Breast Cancer Res Treat. 2020 Apr;180(3):777-790
pubmed: 32086655
N Engl J Med. 2016 Jul 21;375(3):209-19
pubmed: 27264120
Psychol Test Assess Model. 2016;58(1):183-219
pubmed: 28649483
J Natl Cancer Inst. 2019 May 1;111(5):498-508
pubmed: 30239824
Oncol Nurs Forum. 2008 Jul;35(4):635-42
pubmed: 18591167
Med Care. 2013 Aug;51(8 Suppl 3):S73-9
pubmed: 23774513
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
J Clin Oncol. 2016 Jul 20;34(21):2452-9
pubmed: 27217455
Breast Cancer Res Treat. 1999 May;55(2):189-99
pubmed: 10481946
Breast Cancer Res Treat. 2021 Jan;185(1):53-62
pubmed: 32918659
Tumori. 2015 Sep-Oct;101(5):469-73
pubmed: 26108239
Breast Cancer Res Treat. 2013 Sep;141(2):173-85
pubmed: 24013707
Psychooncology. 2013 Apr;22(4):895-901
pubmed: 22544513
Chest. 2011 Jun;139(6):1368-1379
pubmed: 21454401
Cancer. 2014 Aug 15;120(16):2403-11
pubmed: 24802413
Sleep Med Rev. 2016 Jun;27:20-8
pubmed: 26434673
J Cancer Surviv. 2016 Jun;10(3):573-82
pubmed: 26644190
Br J Cancer. 2013 Apr 16;108(7):1515-24
pubmed: 23519057
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD008465
pubmed: 22895974
J Clin Oncol. 2011 Mar 20;29(9):1216-20
pubmed: 21343558
Breast Cancer. 2016 Jan;23(1):128-133
pubmed: 24934610
J Clin Oncol. 2006 Jun 20;24(18):2815-21
pubmed: 16782919
Clin Breast Cancer. 2017 Aug;17(5):350-355.e4
pubmed: 28365336
Breast Cancer Res Treat. 2013 Feb;138(1):185-91
pubmed: 23334803
Breast Cancer Res Treat. 2012 Jul;134(2):459-78
pubmed: 22689091
J Clin Oncol. 2008 Feb 1;26(4):556-62
pubmed: 18180462
Oncol Nurs Forum. 2017 May 1;44(3):E101-E110
pubmed: 28635973
Breast Cancer Res Treat. 2011 Jul;128(2):553-61
pubmed: 21311968
J Clin Oncol. 2017 Aug 10;35(23):2666-2673
pubmed: 28661758
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Breast Cancer Res Treat. 2015 Jul;152(2):231-7
pubmed: 26067931
J Clin Oncol. 2012 Mar 20;30(9):936-42
pubmed: 22331951
Qual Life Res. 2015 May;24(5):1207-16
pubmed: 25398495
Clin Breast Cancer. 2016 Aug;16(4):247-255.e3
pubmed: 27133733
J Clin Oncol. 2015 Jan 10;33(2):165-71
pubmed: 25452447
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1266-1275
pubmed: 28515111
Oncol Nurs Forum. 2014 May;41(3):274-85
pubmed: 24769592